**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 16717**

**Columns: EDITORIAL**

**Portal vein thrombosis in cirrhosis: Controversies and latest developments**

Harding DJ *et al.* Portal vein thrombosis in cirrhosis

Damian J Harding, M Thamara PR Perera, Frederick Chen, Simon Olliff, Dhiraj Tripathi

**Damian J Harding, M Thamara PR Perera, Dhiraj Tripathi,** Liver Unit, Queen Elizabeth Hospital, Birmingham B15 2TH, United Kingdom

**Frederick Chen,** Department of Haematology, Queen Elizabeth Hospital, Birmingham B15 2TH, United Kingdom

**Simon Olliff,** Department Imaging and Interventional Radiology, Queen Elizabeth Hospital, Birmingham B15 2TH, United Kingdom

**Author contributions:** All authors contributed to the manuscript.

**Conflict-of-interest:** Tripathi D and Olliff S have received speaker fees from Gore Medical. The other authors have not declared have any potential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Dr. Dhiraj Tripathi,** Liver Unit, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Edgbaston, Birmingham B15 2TH, United Kingdom.dhiraj.tripathi@uhb.nhs.uk

**Telephone**: +44-121-3714645

**Fax**: +44-121-4141833

**Received:** January 27, 2015

**Peer-review started:** January 28, 2015

**First decision:** February 10, 2015

**Revised:** March 12, 2015

**Accepted:** May 7, 2015

**Article in press:**

**Published online:**

**Abstract**

Portal vein thrombosis is encountered in liver cirrhosis, particularly in advanced disease. It has been a feared complication of cirrhosis, attributed to significant worsening of liver disease, poorer clinical outcomes and potential inoperability at liver transplantation; also catastrophic events such as acute intestinal ischaemia. Optimal management of portal vein thrombosis has not yet been addressed in any consensus publication. Review current literature on portal vein thrombosis in cirrhosis; its prevalence, pathophysiology, diagnosis, impact on the natural history of cirrhosis and liver transplantation, and management. Studies were identified by a search strategy using MEDLINE and Google Scholar. The incidence of portal vein thrombosis increases with increasing severity of liver disease: less than 1% in well-compensated cirrhosis, 7.4%-16% in advanced cirrhosis. Prevalence in patients undergoing liver transplantation 5%-16%. Portal vein thrombosis frequently regresses instead of uniform thrombus progression. Portal vein thrombosis is not associated with increased risk of mortality. Optimal management has not been addressed in any consensus publication. We propose areas for future research to address unresolved clinical questions.

**Key words:** Portal vein thrombosis; Liver cirrhosis; Anticoagulation; Transjugular intrahepatic portosystemic stent-shunt

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Portal vein thrombosis is a complication of liver cirrhosis. Optimal management of portal vein thrombosis in cirrhosis has not been addressed in any consensus publication.There has been recent interest in the impact of portal vein thrombosis on the natural history of cirrhosis, and several authors have now described specific treatments for portal vein thrombosis, particularly with transjugular intrahepatic portosystemic stent-shunt and anticoagulation.We review current literature on portal vein thrombosis in cirrhosis and propose areas for future research to address unresolved clinical questions.

Harding DJ, Perera MTP, Chen F, Olliff S, Tripathi D. Portal vein thrombosis in cirrhosis: Controversies and latest developments. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Portal vein thrombosis (PVT) is a relatively common finding in advanced cirrhosis, often found in asymptomatic subjects as part of routine ultrasonography. There has been no published consensus on non-malignant PVT in cirrhosis.

We aim to provide an analysis of the current literature and explore options for optimal management of non-malignant PVT in cirrhosis. Literature was identified by a search strategy using MEDLINE and Google Scholar using search terms that included “liver cirrhosis” OR “cirrhosis” AND “portal vein” AND “thrombosis” OR “venous thrombosis” OR “embolism and thrombosis.” Eligible studies referred to aspects of the incidence and prevalence, pathophysiology, aetiology, diagnosis and management of portal vein thrombosis in cirrhosis. Because liver transplantation is an important treatment for cirrhosis, studies that referred to portal vein thrombosis and liver transplantation were also eligible. Studies that referred to non-cirrhotic or hepatocellular carcinoma-related portal vein thrombosis were excluded. We identified 2967 search results with MEDLINE and 2860 results with Google Scholar.

**ANATOMY**

The portal vein is a valveless, approximately 6-8 cm long conduit that arises from the confluence of the superior mesenteric and splenic veins posterior to the neck of the pancreas. It accounts for 75% of the blood supply to the liver. In the porta hepatis, the portal vein divides into right and left branches that ultimately empty into the hepatic sinusoids of the right and left lobes respectively[1].

Portal vein thrombosis is a condition caused by the formation of blood clot within the extra-hepatic portion of the portal vein. In the presence of cirrhosis, PVT is most commonly associated with portal vein stasis, or caused by tumour invasion from hepatocellular carcinoma or portal vein occlusion by cholangiocarcinoma in patients with primary sclerosing cholangitis. PVT may also occur following ablative therapy for hepatocellular carcinoma or fine needle aspiration of pancreatic mass[2,3]. PVT can also occur as an unusual condition in non-cirrhotic individuals: in the Western Hemisphere there is commonly an underlying pro-thrombotic aetiology or local intra-abdominal inflammation, such as pancreatitis or cholangitis. In Southern Asia omphalitis from neonatal umbilical sepsis or cannulation is a cause of childhood PVT[4]. Tumour-related and non-cirrhotic PVT is not further discussed in this review.

**INCIDENCE AND PREVALENCE**

There have only been limited studies of the incidence and natural history of portal vein thrombosis in cirrhosis. A prospective study of 1243 patients with Child’s A and B cirrhosis found the cumulative incidence of new PVT after 1 and 5 years 4.6% and 10.7% respectively[5]. Another prospective study of 73 cirrhotics, with a mean baseline MELD score of 15.1, showed an annual incidence of 16%[6]. In one cohort of 251 patients with cirrhosis listed for transplantation the incidence of new portal vein thrombosis was 7.4% during a mean follow up of 12 months[7]. The cumulative incidence of PVT after 1 year was 12.8% in a study by Maruyama *et al*[8] that followed 150 patients with viral hepatitis-related cirrhosis and no baseline PVT. The risk of developing PVT has been related to the severity of liver disease, with a risk less than 1% in those with well-compensated cirrhosis[9].

The prevalence of PVT in cirrhotic populations is between 0.6 to 26%[10]. In studies published since 2000 the prevalence of PVT in patients undergoing transplantation or evaluation for transplantation is between 5 to 16%[11-16].

**PATHOPHYSIOLOGY**

***Acute phase***

In acute PVT there is new formation of either partially or completely occlusive thrombosis in the portal vein. The episode may be asymptomatic, or may be associated with abdominal pain –particularly if the superior mesenteric vein is involved. Acute obstruction of the superior mesenteric vein and mesenteric arches can lead to intestinal ischaemia, and life-threatening infarction: this seldom occurs in patients with cirrhosis where the onset and progression of PVT is a more gradual and slower process, allowing alternative venous drainage to be established.

Following acute complete occlusion of the portal vein there is intense compensatory hepatic arterial vasodilatation (“arterial rescue”) that stabilises liver function.

***Chronic phase***

After the period of arterial vasodilatation a phase of “venous rescue” follows with formation of venous collaterals that bypass the occluded segment, forming a “cavernoma” in 3 to 5 weeks. For practical purposes an acute PVT can be differentiated from chronic PVT by the absence or presence of a cavernoma of porto-portal collateral vessels on imaging[17,18].

***Complications of portal vein thrombosis***

Complications of portal vein thrombosis include variceal haemorrhage, intestinal ischaemia and portal biliopathy (enlarged collateral veins on the surface of the common bile duct causing partial or complete bile duct obstruction)[19]. There is conflicting evidence regarding the role of PVT in the natural history of cirrhosis (see below). It has been reported that subjects with cirrhosis and PVT are at an increased risk of variceal haemorrhage compared with cirrhotics without PVT[20]. The incidence of intestinal ischaemia following PVT is not widely reported. Harki *et al*[21] prospectively assessed for symptoms and clinical evidence of ischaemia (by measuring small intestinal mucosal saturation measurements with visible light spectroscopy). In their small cohort (*n* = 17) of subjects with non-malignant, non-cirrhotic PVT, 67% had both exercise-induced abdominal pain and low visible light spectroscopy findings consistent with ischaemia.No similar studies have been reported. The risk of intestinal infarction has not been well characterised for reasons explained earlier. Prospective studies have not identified cases of intestinal infarction[8,22]. A retrospective study of databases from 11 hospitals in Sweden reported on 176 patients with PVT over a median 2.5 years. Abdominal pain was less common in cirrhotic than non-cirrhotic patients. 3% of the cohort required bowel resection for intestinal ischaemia or infarction[23].

**AETIOLOGY OF PORTAL VEIN THROMBOSIS IN CIRRHOSIS**

***Venous stasis***

Cirrhosis is associated with increased intra-hepatic vascular resistance and reduced portal blood flow into the liver[24]. Low portal blood flow seems to be the most important risk factor for PVT in cirrhosis and has been found to be predictive of future PVT[6,25,26].

Many patients with cirrhosis are treated with non-selective beta-blockers, which reduce portal blood flow and velocity[27]. The role of non-selective beta-blockers in influencing survival in patients with decompensated cirrhosis remains controversial; whether they are implicated in the pathogenesis of PVT has not been evaluated with the exception of Nery *et al*[5] who did not find any association between the use of non-selective beta-blockers and the development of PVT[10,28-30].

***Thrombophilia***

Levels of both pro- and anti-coagulation proteins are reduced in cirrhosis with impaired synthetic function, usually with maintained haemostatic balance and no tendency for bleeding or thrombosis[31]. Thrombin generation in cirrhosis is only impaired in the presence of severe thrombocytopenia[32]. The international normalized ratio (INR) in liver disease likely overestimates the risk of bleeding because the international sensitivity index used is determined by means of plasma from patients on vitamin K antagonists[33]. Other conventional coagulation tests in patients with cirrhosis do not take into account the reduction in anti-coagulant proteins[34].

Several large population studies have demonstrated that the incidence of venous thromboembolism (deep vein thrombosis, pulmonary embolism) in individuals with cirrhosis is at least similar to that in subjects without liver disease[35-38].

Factor VIII is an important pro-coagulant involved in thrombin generation. Concentrations of factor VIII increase progressively with worsening cirrhosis[39]. Protein C is an important anti-coagulant: levels of protein C are often reduced in cirrhosis[40]. The ratio of factor VIII to protein C may be predictive of a hypercoagulability[41].

Some pro-thrombotic genotypes, including factor V Leiden G1691A mutation, methylenetetrahydrofolate reductase TT677 mutation and prothrombin G20210A mutation may be more frequent in cirrhotic patients with PVT compared with cirrhotic patients without PVT[42-44].

Anticardiolipin antibodies may be more common in PVT in cirrhosis[45]. Bacteraemia from bacteroides fragilis has been associated with an increased risk of PVT due to transient appearance of anticardiolipin antibodies[46]. However in a prospective longitudinal study of cirrhotic patients in France and Belgium the presence of G20210A prothrombin or factor V mutations was not associated with the development of PVT[5].

***Endotoxinaemia***

Bacterial translocation and endotoxinaemia are common with worsening liver disease, as a result of intestinal mucosal barrier damage[47-50]. Inflammation from bacterial infection increases portal pressure[51-53].

Portal endotoxinaemia may facilitate activation of the coagulation cascade within the portal venous system[54]. Villa *et al*[55] demonstrated that the use of enoxaparin in cirrhosis was associated with reduced bacterial translocation, and proposed that this was because of improvements in intestinal microcirculation sufficient to ameliorate portal hypertensive enterocyte damage[55]. Reducing portal pressure with non-selective beta blockers is associated with a reduced risk of spontaneous bacterial peritonitis or bacteraemia[56,57].

**HISTORICAL RISK FACTORS FOR PVT IN CIRRHOSIS**

Reported historical risk factors for PVT in cirrhosis include complications of, and previous treatments for complications of portal hypertension (previous variceal haemorrhage, endoscopic sclerotherapy, splenectomy, shunt surgery) and the presence of hepatocellular carcinoma[7,15,26].The presence of hepatocellular carcinoma (in the absence of macro-vascular invasion) appears to be a risk factor for non-neoplastic PVT[13]. Severity of underlying cirrhosis, and time spent on a waiting list for liver transplantation are risk factors for PVT[7,58 ].

Low platelet count, and the development of collateral vessels have been associated with increased risk of developing PVT[7,8].These findings are compatible with the presence of reduced portal blood flow in cirrhosis with portal hypertension, likely the most important causative factor for PVT in cirrhosis[6].

**DIAGNOSIS AND SCREENING**

Imaging is appropriate as part of the initial evaluation of subjects with cirrhosis, and periodically during follow up. Because of the risk of hepatocellular carcinoma in cirrhosis CT or MRI evaluation is advisable following new ultrasound diagnosis of PVT, to look for the presence of liver tumour. Endoscopic screening for varices should also take place because of the increased risk of varices in the presence of cirrhosis with PVT.

***Ultrasound and doppler ultrasound***

Ultrasound and Doppler ultrasound are usually sufficient to diagnose PVT according to published series, however the incidence of PVT is much higher than that is routinely detected by above means[59,60]. Ultrasound may demonstrate hyperechoic material in the vessel lumen, but there is variation and operator dependent aspect to this diagnosis. Most of the diagnosis is reliant on Doppler scan that demonstrates absence of flow in part of, or all of the lumen. It can also show flow velocity and direction. “False negatives” have been reported with ultrasound at the time of transplantation[14]. Such findings may occur because of de novo thrombus formation between imaging and transplantation or false negatives. Different grades of PVT (discussed below) further complicate these findings. Using three-monthly Doppler ultrasound on their cohort of 251 cirrhotic patients awaiting transplantation, Francoz *et al*[7] diagnosed PVT in 9 patients at the time of transplantation. Eight of these patients had only partial thrombosis: transplantation was technically feasible in all cases.Data from 1491 patients who underwent liver transplantation at Queen Elizabeth Hospital Birmingham between January 2000 to August 2012 show a PVT prevalence of 119 (8%). Thirty-four (29%) of these cases were diagnosed at the time of surgery. For these subjects the mean interval from last screening imaging to transplantation was 2.25 mo. This suggests that some of the PVTs diagnosed are “interval” thromboses. Overall there were no survival differences between “diagnosed”, “incidental” PVT cases and matched controls without PVT[61].

***Cross-sectional imaging***

Multiphase computed tomography (CT) is alternatively recommended to diagnose PVT during evaluation of cirrhosis. Ultrasound is accurate detecting thrombus in the trunk of the portal vein and intrahepatic branches. CT better assesses the superior mesenteric vein, the presence of porto-systemic shunts, renal veins and inferior vena cava, and the extent of thrombus. CT can help diagnose hepatocellular carcinoma and intestinal ischaemia[62,63].

Magnetic resonance imaging (MRI) is an alternative to CT, although has reduced definition in the presence of significant ascites[64].

MRI with contrast is helpful for demonstrating the portal venous system flow and thrombus like CT. MRI is advised for repeated imaging in younger patients to avoid the radiation associated with repeated CTs.

**EFFECTS OF PORTAL VEIN THROMBOSIS ON THE NATURAL HISTORY OF CIRRHOSIS**

The effects of PVT on the natural history of cirrhosis, including its effects on survival may not be deleterious. The risk of PVT appears to increase with severity of cirrhosis[9], but there is little data to demonstrate that PVT is an independent prognostic factor in cirrhosis[16,65].

***Effects on Survival***

A review, using UNOS registry data from 2002 to 2013 of 66,506 patients without hepatocellular carcinoma who were awaiting liver transplantation, found that the presence of PVT was not associated with an increased risk of death or reduced chance of undergoing transplantation[66].

Maruyama and colleagues followed up 150 patients with viral hepatitis-related cirrhosis, without PVT at baseline. Of the 42 (28%) patients who developed PVT the thrombus progressed in 7.2%, was unchanged in 45.2% and improved in 47.6%. The cumulative survival rates were similar between the thrombosis and non-thrombosis groups[8].

***Effects on disease progression***

In a prospective study of 1243 patients with cirrhosis and a mean follow-up of 47 mo, the development of PVT was not associated on multivariate analysis with the risk of disease progression. 118 subjects developed a new PVT, of which 87 were non-occlusive (one year cumulative incidence 4.6%). Non-occlusive thrombus varied over time, disappearing on follow-up in 70% of cases[5].

Natural history studies have identified relatively high rates of PVT regression instead of uniform thrombus progression. One study of 42 consecutive patients with cirrhosis (mean MELD 12.1; range 7-20) and untreated extra-hepatic, non-malignant PVT followed up subjects for a mean 27 mo. PVT worsened in 48% of patients and improved in 45%. There was no clear association between progression or regression of PVT and clinical outcome, with baseline Child-Pugh score the only independent predictor of survival or hepatic decompensation[22].

The positive findings of a study that examined the effects of primary prevention of PVT with anticoagulation in subjects with cirrhosis might suggest that PVT does have a role in the progression of cirrhosis: improved survival and less episodes of hepatic decompensation were seen in the study’s active arm[55].However the study’s authors did not attribute the difference in hepatic decompensation to the prevention of PVT: they postulated that enoxaparin therapy lead to improved intestinal microcirculation and endothelial function, which had a protective effect on the course of the liver disease by reducing bacterial translocation. No other published studies have confirmed their findings.

***Complications***

The presence of PVT has been associated with a longer time to achieve endoscopic eradication of varices, but once achieved did not influence their recurrence[67].

The potential for life-threatening intestinal infarction in the presence of complete thrombus occlusion of the portal and superior mesenteric veins is known, although the actual risk of this event is not known.

Sudden clinical deterioration in a cirrhotic patient, such as the development of diuretic resistant ascites or bacterial peritonitis is suggestive of the development of PVT and should be thoroughly evaluated. The PVT may be the cause of, or the consequence of such events. A stable patient on diuretics may develop a PVT leading to diuretic resistance, leading to SBP. On the other hand bacterial infection in the peritoneum may lead to development of PVT.

**IMPACT OF PORTAL VEIN THROMBOSIS ON LIVER TRANSPLANTATION**

PVT, particularly complete thrombosis affects rates of complications, and possibly survival with liver transplantation. It was historically seen as a contraindication to transplantation.

***Surgical considerations***

The Yerdel classification of PVT is widely used to describe PVT because it correlates thrombosis extent with surgical technique and risk of complications (Figure 1)[15].

Pre-existing knowledge of a patient’s portal vein thrombosis and use of the Yerdel classification allows appropriate graft selection and planning of the transplant surgical procedure. (Intra-operative diagnosis of incidental PVT may cause problems of added surgical explant time, increased risk of significant bleeding and prolonged cold ischaemia time for the selected graft.) For Yerdel grades I to III, operative techniques include thrombectomy, with or without creation of an interposition graft, followed by direct porto-portal anastomosis. In cases where the lumen of the portal vein has been narrowed by cicatrisation of the thrombus, the narrowed segment can be resected and a donor iliac vein graft used as an interposition graft, resulting in a patent, larger diameter vein. Thrombectomy is still possible with Yerdel grade III PVT as long as the portal vein is carefully examined down to the junction of the superior mesenteric and splenic veins with extraction of all thrombus.

Cases of Yerdel grade IV and some grade III cases may be considered as contraindications to transplantation in some centres, while taken on by experienced high volume centres. Complex vascular reconstruction techniques may be necessary with meso-portal “jump grafts” from donor veins or synthetic vascular grafts, creation of porto-caval shunt or portal vein arterialisation. Such complex procedures for extensive or grade IV PVT carry a high (approximately 50%) risk of post-transplant portal hypertension[16].There are a few case series of patients with diffuse PVT who have undergone multivisceral transplantation[68]. The procedure is only offered in a few centres, but should be considered in patients with severe bowel dysfunction due to porto-mesenteric venous ischaemia or refractory portal hypertensive gastrointestinal bleeding where diffuse PVT is present.

***Outcomes of liver transplantation with portal vein thrombosis***

A large American series described outcomes post-liver transplantation between September 2001 and December 2007 in 22291 subjects where the prevalence of PVT was 4.02% (n = 897). PVT was not classified according to grade, or whether occlusive/non-occlusive. The presence of PVT was associated with higher post-transplant mortality only during the first year of follow up in this cohort (HR = 1.32, *P* = 0.02)[65]. Our own institution’s experience of 1491 transplants between January 2000 and August 2012 found the presence of PVT was associated with significant increases in intra-operative blood product use and theatre time, but no difference in survival[61].

Several papers describe outcomes based upon the classification of thrombosis. In subjects with non-occlusive PVT, post-transplant mortality outcomes are no different from non-PVT patients[15,69,70].

Mortality rates likely increase in the presence of occlusive PVT, but may be better in larger centres with greater experience of PVT-surgical management. In a review of 25753 transplants performed in different centres between 1984 and 2008 the 30 d and 1 year mortality rates for subjects with PVT were higher than for those without PVT (10.5% and 18.8% *vs* 7.7% and 15.4%): only complete PVT accounted for this difference[69]. Mortality rates were higher still in subjects with grade IV PVT. Studies of transplant recipients where end-to-end portal anastomoses were not feasible describe high rates of post-operative morbidity due to persistent portal hypertension, and higher rates of early post-operative mortality (25%)[71-73]. More recent data from high volume centres with specific experience in PVT-surgical treatment do not show any effect of PVT on survival. Two studies provide analysis of outcomes for patients with Yerdel grades 3 and 4 PVT. Outcomes for these centres have improved: Ravaioli *et al*[13] showed no survival differences for patients with complete PVT when their 10 year data were restricted to the last 5 years (Table 1)[13].

***Portal vein thrombosis following liver transplantation***

Thrombosis of the portal vein, particularly early following transplantation carries a poor prognosis[74]. The rate of PVT occurrence post-transplantation in subjects without a history of preceding PVT is between 0-2%[12,14,15,75]. PVT post-transplantation can occur at the anastomosis site when there is significant mismatch of the donor: recipient vein diameters[76]. The rate of post-transplant PVT recurrence in subjects with previous PVT is higher: 2%-3%[14,61,77,78]. It is not clear whether thrombosis rates are greater following more complex procedures. There are no standardised approaches to post-liver transplant prevention of re-thrombosis. It is expected that the risk of recurrent portal vein thrombosis should be reduced by the correction with transplantation of the haemodynamic abnormalities associated with cirrhosis and portal hypertension. In considering approaches to managing the risk of PVT recurrence, they should be weighed against risks of post-operative bleeding.

**LIVING DONOR TRANSPLANTATION AND PVT**

Living donor transplantation is performed in many centres because of a shortage of cadaveric donors. For the safety of donors partial grafts obtained from living donors have only a very short length of portal vein. To complete the anastomosis it is vital that there is an adequate length of recipient portal vein, which is not always feasible, particularly in the presence of recipient portal vein thrombosis[79]. Procurement of additional vessels to allow complex interposition or jump grafts is also limited, making living donor liver transplantation for patients with complete portal vein thrombosis technically more difficult with high reported mortality. Outcomes in the presence of partial PVT are similar to those in recipients without PVT[80]. For cases of complete PVT the use of re-canalised umbilical vein, saphenous vein of the donor or the recipient, or the hepatic veins of the explanted cirrhotic liver have all been used. Another option is to use the cryopreserved vessels from cadavers or cadaveric donors but their use has been associated with worse outcomes due to an increased risk of re-thrombosis[81].

**MANAGEMENT OF PORTAL VENOUS THROMBOSIS IN CIRRHOSIS**

The natural history of PVT in cirrhosis remains controversial: this has affected the ability to provide clear management consensus. The presence of PVT does affect liver transplantation surgery and potentially outcome. In candidates for transplantation the main objective of management is to achieve at least partial recanalization to allow portal flow to the graft with a conventional end to end PV anastomosis. If recannalisation cannot be achieved the objective is to prevent extension of thrombus, particularly to the superior mesenteric vein. Careful screening during evaluation and throughout follow up is important to achieve these aims. In patients with PVT there are different possible approaches to treatment: anticoagulation, transjugular intrahepatic portosystemic stent-shunt (TIPSS), and endovascular procedures with fibrinolysis. The use of primary preventative strategies could also be considered for patients at risk of developing PVT.

PVT in cirrhosis is associated with a higher risk of variceal haemorrhage than in cirrhotic individuals without PVT: assessment with upper gastrointestinal endoscopy is warranted to assess for oesophageal varices[82].

**ANTICOAGULATION**

Six published studies describe anticoagulation in 199 cirrhotic patients using warfarin (with target INR 2-3) or low molecular weight heparin for means of between 6 months to 302 days[7,55,83-86]. Two case reports describe the use of rivaroxaban, an oral factor Xa inhibitor, in the management of acute PVT in six subjects with well-compensated Child’s A cirrhosis[87,88]. With the exception of studies reported by Villa *et al*[55] and Senzolo *et al*[85], all of the reported studies are case-control or retrospective series of subjects with cirrhosis and partial or occlusive acute PVT. These published studies do not describe treatment of chronic PVT associated with cavernoma.

***Primary prevention***

Villa *et al*[55] performed a randomised, controlled study of enoxaparin (4000 IU daily) for 48 wks in 70 patients with Child’s B7 to C10 cirrhosis and no PVT (34 active arm, 36 controls). The study’s primary outcome, prevention of PVT in subjects with cirrhosis, was successful: there were no PVTs in the active arm at the end of follow up (at 2 years), compared with the 27.7% rate of PVT in the control arm. Of clinical importance, rates of hepatic decompensation (ascites, encephalopathy, bacterial peritonitis, portal hypertensive bleeding) were significantly lower in the treatment arm (38.2%) compared with controls (83%, *P* < 0.0001). Treatment with enoxaparin was associated with a reduction in bacterial translocation, which was thought at least partly responsible for the lower rates of decompensation. No relevant side effects or haemorrhagic events were reported.

***Secondary prevention***

Senzolo *et al*[85] prospectively evaluated treatment with low molecular heparin (nadraparin) for at least 6 months compared with standard care in 35 actively treated and 21 control subjects. The patients had cirrhosis (mean MELD 12.6 active arm) and either partial or complete acute PVT. In the active arm the incidence of complete recannalisation was 60%, with stabilisation or partial recannalisation achieved in 20%. Amongst controls recannalisation occurred in only one subject (5%) with partial recannalisation or stabilisation in 5 (24%): the incidence of thrombus progression in controls was 71.4%.

Amongst the reported studies of anticoagulation therapy for secondary prevention, treatment was associated with recanalization rates of between 39.3% to 75%, and an incidence of thrombus progression between 0 and 14.3%. This compares favourably with rates of recanalization or thrombus progression reported for control subjects by Senzolo *et al*[85].

Amitrano *et al*[83] and Senzolo *et al*[85] reported a mean time until venous repermeation of 6.5 and 5.5 mo respectively. Delgado *et al*[84] reported that that up to 39% of subjects who had achieved portal vein recanalization developed re-thrombosis after stopping anti-coagulation. Where assessed for, the prevalence of thrombophilic abnormalities was between 5 and 16%.(Werner and Delgado)[84,86]

***Complications***

With the exception of the study reported by Delgado *et al*[84], all study patients were screened for large varices, with endoscopic obliteration provided before commencement of anticoagulation. Patients with cavernoma were generally excluded. Patients in the study by Delgado et al received standard primary or secondary management of varices following recognised international guidelines[89]. In the studies of patients who received pre-emptive endoscopic obliteration of varices (*n* = 144) there were 4 episodes of variceal haemorrhage on treatment. There were 6 episodes of variceal haemorrhage amongst the 57 control subjects.

Senzolo *et al*[85] report one cerebral haemorrhage leading to hemiparesis on treatment. Other bleeding complications on treatment were: 2 epistaxis (1 epistaxis in a control subject), 1 haematuria, 2 significant vaginal bleeding, 1 obscure and 1 lower gastro-intestinal haemorrhage. Among the control subjects there were 2 episodes of intestinal ischaemia (one fatal), and two subjects went on to have liver transplantation that required caval hemi-transposition. Delgado *et al*[84] identified baseline platelet count of < 50 × 109/L as a risk factor for bleeding complications.

In the study reported by Senzolo *et al*[85]  control patients experienced greater rates of complications than the active arm: 2 of the 21 controls developed intestinal ischaemia (one fatal), and 2 required caval hemitransposition at liver transplantation. Delgado *et al*[84] study showed that complications associated with deteriorating cirrhosis were more common in patients who did not achieve recanalization.

***New oral anti-coagulants***

These agents work by direct inhibition of thrombin or activated factor Xa, and are licenced for the prevention of primary or recurrent venous thromboembolism, or prevention of stroke in non-valvular atrial fibrillation[90-93]. Their practical advantages include oral administration, the lack of any requirement for monitoring with blood tests, and no effect on INR, an important component of the MELD score. The new oral anticoagulants have no antidote: of clinical importance when considering individual patients’ risks of bleeding complications[94]. However specific antidotes, such as Andexanet Alfa (Clinicaltrials.gov: NCT01758432) are under development. The new oral anti-coagulants can be affected by drugs that are P-glycoprotein substrates. Drugs that inhibit or induce CYP3A4 can significantly affect concentrations or effects of rivaroxaban[95]. The potential for drug interaction is important to consider for patients intending to commence new directly acting antiviral therapies for hepatitis C (Table 2)[96].

Recent case reports describe the use of rivaroxaban to treat acute PVT in well-compensated cirrhosis. Unfortunately for patients with severe liver disease the drug has not been evaluated in decompensated cirrhosis, where concerns exist that its pharmacological effects will be altered[97,98].

From these small studies and series it is clear that anticoagulation with warfarin or low molecular heparin is feasible in cirrhosis, may prevent the onset of PVT or its extension once present, and may even slow down progression of liver cirrhosis. Further controlled studies with larger numbers are indicated to validate these findings. These published experiences may justify the current use of anticoagulation in some settings such as cirrhotics with partial or occlusive PVT who are on transplant waiting lists. There is no consensus on which anticoagulant is best: low molecular weight heparin can be given until transplantation, but requires administration of an injection. Warfarin impacts upon patients’ MELD scores and requires monitoring of INR. Rivaroxaban cannot be provided to patients with decompensated cirrhosis (Table 2).

***Transjugular intrahepatic portosystemic stent-shunt***

Transjugular intrahepatic portosystemic stent-shunt (TIPSS) (with bare or covered stents) may be a treatment option to manage PVT as an alternative to anticoagulation, particularly in the presence of severe complications of portal hypertension (recurrent or refractory variceal haemorrhage or ascites), or contraindications to anticoagulation. The goal of TIPSS is to repermeate the portal vein and restore portal flow through the low resistance shunt, thereby preventing recurrent thrombosis. TIPSS may have a role in liver transplant candidates in maintaining portal vein patency, avoiding PVT propagation, and enhancing the feasibility of transplantation. TIPSS may even be feasible in some patients with cavernoma[99,100]. TIPSS can prevent total portal vein occlusion in liver transplantation candidates with partial PVT[101]. There are no studies that compare anticoagulation, TIPSS, or conservative treatment in the management of PVT in cirrhosis.

***Outcomes***

Experience of TIPSS in more than 200 subjects with cirrhosis and PVT has been published[99-106]. Rates of feasibility between 70% to 100% are described. Successful TIPSS placement is associated with clinical improvement, low rates of re-thrombosis, and low rates of recurrent portal-hypertensive bleeding. Because of the low rates of re-thrombosis following complete portal vein recanalization, systemic anticoagulation following TIPSS is probably only indicated in the presence of a documented pro-thrombotic state[101-103].

The use of TIPSS has been described in cirrhotic patients with PVT and complications of portal hypertension, bleeding or ascites. A small number of individuals have undergone TIPSS with the aim of preventing complete occlusive PVT while awaiting liver transplantation[102,105]. D’Avola *et al*[102]describe TIPSS in 15 cirrhotic subjects with partial PVT waiting for transplantation. These individuals were compared with 8 matched controls who did not undergo TIPSS. There were no significant complications associated with the TIPSS procedure. There were no differences between the groups’ post-transplantation outcomes, transplant operating times or use of blood products. Wang *et al*[105] compared a group of 25 patients with cirrhosis and PVT who were treated successfully with TIPSS with a cohort of 25 patients with cirrhosis and PVT who were managed conservatively including endoscopic variceal ligation). Successful TIPSS was associated with portal vein recannalisation and not surprisingly lower rates of variceal bleeding. Interestingly there were no differences in survival between the two groups, which were followed up for a mean of 25.1 mo (Table 4).

While elective TIPSS use in cirrhosis carries a higher risk with high MELD scores[106], between 16% to 33% of cases where baseline severity of liver disease was recorded had baseline Child’s C disease severity.

***Complications and technical failure***

Technical failure has been associated with extensive main portal vein thrombosis[100], and the absence of a patent intra-hepatic portal vein branch that can be punctured[101,103,105]. TIPSS placement may compromise an intended liver transplant procedure if it is sited distally into the portal vein trunk and superior mesenteric vein[108].Lower rates of success are reported in the presence of cavernoma[100,101]. Reduced rates of TIPSS dysfunction have been reported with the use of covered stents[103].

Unlike anticoagulation, TIPSS is associated with a risk of developing hepatic encephalopathy[109]. Han *et al*[99] and Luca *et al*[102] reported rates of post-TIPSS encephalopathy between 25% to 32%, although Senzolo *et al*[104]reported only one out of 28 subjects developing encephalopathy in their series of both cirrhotic and non-cirrhotic patients.

**ENDOVASCULAR FIBRINOLYSIS**

Results from published experiences of thrombolysis in non-cirrhotic patients have been disappointing with high incidence of major bleeding complications and low rates of recanalization[110-112]. Experience of thrombolysis, alone or in conjunction with TIPS, in cirrhotic patients with PVT is limited[113,114].

**CONCLUSION**

PVT is a common problem in patients with advanced cirrhosis, with diagnosis occurring more frequently because of the greater prevalence of ultrasound screening in cirrhosis. While PVT has been associated with some important clinical complications, including worsening portal hypertension (at least in the short term), mesenteric infarction and portal biliopathy; its overall prognostic significance is still not fully understood. PVT is clinically relevant where liver transplantation is anticipated.

While reduced portal vein velocity is likely the most important risk factor for PVT in cirrhosis, other causes such as thrombophilic disorders and endotoxinaemia may play an important role in some individuals. Future studies examining the impact of more targeted use of non-selective beta-blockers in advanced cirrhosis, or strategies aimed at reducing bacterial translocation in cirrhosis may demonstrate a beneficial impact on the incidence of PVT[28,115-117]. Larger studies are warranted to repeat the work of Villa and colleagues to establish whether primary prevention of PVT with anticoagulation has a role in selected subjects with cirrhosis[55].

When PVT is first diagnosed in a cirrhotic individual, it is important to ensure that the thrombosis is not associated with the presence of hepatocellular carcinoma: this can be assessed with the use of multiphase CT or MRI liver[118]. Endoscopic screening for varices is warranted. A thrombophilic disorder may be a contributing causative factor –and should be looked for if diagnosis will have longer term clinical implications, for example in liver transplant candidates.

The increasing experience of using specific therapies to prevent or to treat PVT in cirrhotic patients is very interesting. It has been argued that there is sufficient evidence or experience to warrant the use of anti-coagulation in patients with cirrhosis and PVT who are listed for liver transplantation, following prophylactic management of oesophageal varices[20,119]. However in our opinion there remains a lack of adequately powered, randomised studies to demonstrate clearly the role, benefits and risks of anticoagulation or TIPSS to manage PVT in cirrhosis, and whether such interventions are appropriate in all cirrhotics, or appropriate in only certain groups, such as potential liver transplant candidates. There is no clear evidence to support the routine use of anticoagulation or TIPSS in primary prevention.

Prospective cohort studies are warranted to assess the impact of PVT on patients referred for liver transplantation; to evaluate its impact on eligibility for transplantation, on the natural history of patients waiting for transplantation and on outcomes of transplantation.

Randomised controlled studies are warranted to compare current conservative management with the use of anticoagulation or TIPSS to treat acute PVT in cirrhosis. To evaluate outcomes it may be preferable to perform a study in patients referred for or waiting for transplantation. Outcomes of interest should include incidence and maintenance of portal vein repermeation, survival and effects on MELD or progression of underlying liver disease, effects on portal hypertensive complications, and effects on transplant surgery and outcomes. Future study should compare the use of warfarin, low-molecular weight heparin and new oral anti-coagulants.

Some centres routinely provide anti-coagulation to patients with cirrhosis and acute portal vein thrombosis who are waiting for transplantation. It would be useful to combine and publish the available efficacy and safety data from these centres.

Management of PVT in cirrhosis at present remains an individualised decision, according to the risk of thrombus extension, the likelihood of transplantation, and whether there are other clinically significant issues, such as intractable ascites or portal hypertensive bleeding that would warrant use of TIPSS.

**ACKNOWLEDGEMENTS**

We wish to thank Mr Andrew Dakin for assistance with the figures.

**REFERENCES**

1 **Schmidt S**, Demartines N, Soler L, Schnyder P, Denys A. Portal vein normal anatomy and variants: implication for liver surgery and portal vein embolization. *Semin Intervent Radiol* 2008; **25**: 86-91 [PMID: 21326549 DOI: 10.1055/s-2008-1076688]

2 **Shimada T,** Maruyama H, Kondo T, Sekimoto T, Takahashi M, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Chiba T, Kanai F, Okabe S, Yoshikawa M, Yokosuka O. Clinical features and natural history of portal vein thrombosis after radiofrequency ablation for hepatocellular carcinoma in Japan. *Hepatol Int* 2013; **7:** 1030-1039 [DOI: 10.1007/s12072-013-9470-z]

3 **Matsumoto K**, Yamao K, Ohashi K, Watanabe Y, Sawaki A, Nakamura T, Matsuura A, Suzuki T, Fukutomi A, Baba T, Okubo K, Tanaka K, Moriyama I, Shimizu Y. Acute portal vein thrombosis after EUS-guided FNA of pancreatic cancer: case report. *Gastrointest Endosc* 2003; **57**: 269-271 [PMID: 12556803 DOI: 10.1067/mge.2003.79]

4 **Yadav S,** Dutta AK, Sarin SK. Do umbilical vein catheterization and sepsis lead to portal vein thrombosis? A prospective, clinical, and sonographic evaluation. *J Ped Gastroenterol Nutr* 1993; **17**: 392-396 [DOI: 10.1097/00005176-199311000-00010]

5 **Nery F**, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, Plessier A, Roulot D, Chaffaut C, Bourcier V, Trinchet JC, Valla DC. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. *Hepatology* 2015; **61**: 660-667 [PMID: 25284616 DOI: 10.1002/hep.27546]

6 **Zocco MA**, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, Riccardi L, Lancellotti S, Santoliquido A, Flore R, Pompili M, Rapaccini GL, Tondi P, Gasbarrini GB, Landolfi R, Gasbarrini A. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. *J Hepatol* 2009; **51**: 682-689 [PMID: 19464747 DOI: 10.1016/j.jhep.2009.03.013]

7 **Francoz C**, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, Sauvanet A, Valla D, Durand F. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. *Gut* 2005; **54**: 691-697 [PMID: 15831918 DOI: 10.1136/gut.2004.042796]

8 **Maruyama H**, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. *Am J Gastroenterol* 2013; **108**: 568-574 [PMID: 23381015 DOI: 10.1038/ajg.2012.452]

9 **Amitrano L**, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, Grandone E, Balzano A. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. *J Hepatol* 2004; **40**: 736-741 [PMID: 15094219 DOI: 10.1016/j.jhep.2004.01.001]

10 **Garcia-Pagan JC**, Valla DC. Portal vein thrombosis: a predictable milestone in cirrhosis? *J Hepatol* 2009; **51**: 632-634 [PMID: 19660824 DOI: 10.1016/j.jhep.2009.06.009]

11 **Molmenti EP**, Roodhouse TW, Molmenti H, Jaiswal K, Jung G, Marubashi S, Sanchez EQ, Gogel B, Levy MF, Goldstein RM, Fasola CG, Elliott EE, Bursac N, Mulligan D, Gonwa TA, Klintmalm GB. Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. *Ann Surg* 2002; **235**: 292-296 [PMID: 11807371 DOI: 10.1097/00000658-200202000-00019]

12 **Tao YF**, Teng F, Wang ZX, Guo WY, Shi XM, Wang GH, Ding GS, Fu ZR. Liver transplant recipients with portal vein thrombosis: a single center retrospective study. *Hepatobiliary Pancreat Dis Int* 2009; **8**: 34-39 [PMID: 19208512]

13 **Ravaioli M**, Zanello M, Grazi GL, Ercolani G, Cescon M, Del Gaudio M, Cucchetti A, Pinna AD. Portal vein thrombosis and liver transplantation: evolution during 10 years of experience at the University of Bologna. *Ann Surg* 2011; **253**: 378-384 [PMID: 21183851 DOI: 10.1097/SLA.0b013e318206818b]

14 **Dumortier J,** Czyglik O, Poncet G, Blanchet MC, Boucaud C, Henry L, Boillot O. Eversion thrombectomy for portal vein thrombosis during liver transplantation. *Am J Transpl* 2002; **2**: 934–938 [DOI: 10.1034/j.1600-6143.2002.21009.x]

15 **Yerdel MA**, Gunson B, Mirza D, Karayalçin K, Olliff S, Buckels J, Mayer D, McMaster P, Pirenne J. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. *Transplantation* 2000; **69**: 1873-1881 [PMID: 10830225 DOI: 10.1097/00007890-200005150-00023]

16 **Francoz C**, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. *J Hepatol* 2012; **57**: 203-212 [PMID: 22446690 DOI: 10.1016/j.jhep.2011.12.034]

17 **Chawla Y**, Duseja A, Dhiman RK. Review article: the modern management of portal vein thrombosis. *Aliment Pharmacol Ther* 2009; **30**: 881-894 [PMID: 19678814 DOI: 10.1111/j.1365-2036.2009.04116.x]

18 **De Gaetano AM**, Lafortune M, Patriquin H, De Franco A, Aubin B, Paradis K. Cavernous transformation of the portal vein: patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography. *AJR Am J Roentgenol* 1995; **165**: 1151-1155 [PMID: 7572494 DOI: 10.2214/ajr.165.5.7572494]

19 **Dhiman RK**, Behera A, Chawla YK, Dilawari JB, Suri S. Portal hypertensive biliopathy. *Gut* 2007; **56**: 1001-1008 [PMID: 17170017 DOI: 10.1136/gut.2006.103606]

20 **Tsochatzis EA**, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. *Aliment Pharmacol Ther* 2010; **31**: 366-374 [PMID: 19863496 DOI: 10.1111/j.1365-2036.2009.04182.x]

21 **Harki J,** Plompen EP, van Noord D, Hoekstra J, Kuipers EJ, Janssen HL, Tjwa ET. Gastrointestinal ischaemia in patients with acute and chronic portal vein thrombosis. *J Hepatol* 2014; **60**: S239–S240 [DOI: 10.1016/S0168-8278(14)60672-3]

22 **Luca A**, Caruso S, Milazzo M, Marrone G, Mamone G, Crinò F, Maruzzelli L, Miraglia R, Floridia G, Vizzini G. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. *Radiology* 2012; **265**: 124-132 [PMID: 22891357 DOI: 10.1016/S0168-8278(12)60648-5]

23 **Rajani R**, Björnsson E, Bergquist A, Danielsson A, Gustavsson A, Grip O, Melin T, Sangfelt P, Wallerstedt S, Almer S. The epidemiology and clinical features of portal vein thrombosis: a multicentre study. *Aliment Pharmacol Ther* 2010; **32**: 1154-1162 [PMID: 21039677 DOI: 10.1111/j.1365-2036.2010.04454.x]

24 **Shah V**. Molecular mechanisms of increased intrahepatic resistance in portal hypertension. *J Clin Gastroenterol* 2007; **41** Suppl 3: S259-S261 [PMID: 17975474 DOI: 10.1097/MCG.0b013e318150d0e1]

25 **Amitrano L**, Guardascione MA, Ames PR. Coagulation abnormalities in cirrhotic patients with portal vein thrombosis. *Clin Lab* 2007; **53**: 583-589 [PMID: 18257465]

26 **Kinjo N**, Kawanaka H, Akahoshi T, Tomikawa M, Yamashita N, Konishi K, Tanoue K, Shirabe K, Hashizume M, Maehara Y. Risk factors for portal venous thrombosis after splenectomy in patients with cirrhosis and portal hypertension. *Br J Surg* 2010; **97**: 910-916 [PMID: 20474001 DOI: 10.1002/bjs.7002]

27 **Bosch J**, Masti R, Kravetz D, Bruix J, Gaya J, Rigau J, Rodes J. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. *Hepatology* 1984; **4**: 1200-1205 [PMID: 6500511 DOI: 10.1002/hep.1840040617]

28 **Sersté T**, Melot C, Francoz C, Durand F, Rautou PE, Valla D, Moreau R, Lebrec D. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. *Hepatology* 2010; **52**: 1017-1022 [PMID: 20583214 DOI: 10.1002/hep.23775]

29 **Ge PS**, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. *J Hepatol* 2014; **60**: 643-653 [PMID: 24076364 DOI: 10.1016/j.jhep.2013.09.016]

30 Leithead JA, Rajoriya N, Tehami N, Hodson J, Gunson BK, Tripathi D, Ferguson JW. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. *Gut* 2014; Epub ahead of print [PMID: 25281417 DOI: 10.1136/gutjnl-2013-306502]

31 **Monroe DM**, Hoffman M. The coagulation cascade in cirrhosis. *Clin Liver Dis* 2009; **13**: 1-9 [PMID: 19150304 DOI: 10.1016/j.cld.2008.09.014]

32 **Tripodi A**, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, Salerno F, Mannucci PM. Thrombin generation in patients with cirrhosis: the role of platelets. *Hepatology* 2006; **44**: 440-445 [PMID: 16871542 DOI: 10.1002/hep.21266]

33 **Arjal R**, Trotter JF. International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure. *Clin Liver Dis* 2009; **13**: 67-71 [PMID: 19150311 DOI: 10.1016/j.cld.2008.09.009]

34 **Tripodi A**. Tests of coagulation in liver disease. *Clin Liver Dis* 2009; **13**: 55-61 [PMID: 19150309 DOI: 10.1016/j.cld.2008.09.002]

35 **Gulley D**, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. *Dig Dis Sci* 2008; **53**: 3012-3017 [PMID: 18443906 DOI: 10.1007/s10620-008-0265-3]

36 **Northup PG**, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, Berg CL. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. *Am J Gastroenterol* 2006; **101**: 1524-158; quiz 1680 [PMID: 16863556 DOI: 10.1111/j.1572-0241.2006.00588.x]

37 **García-Fuster MJ**, Abdilla N, Fabiá MJ, Fernández C, Oliver V. [Venous thromboembolism and liver cirrhosis]. *Rev Esp Enferm Dig* 2008; **100**: 259-262 [PMID: 18662076]

38 **Søgaard KK**, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. *Am J Gastroenterol* 2009; **104**: 96-101 [PMID: 19098856 DOI: 10.1038/ajg.2008.34]

39 **Tripodi A**, Primignani M, Chantarangkul V, Dell'Era A, Clerici M, de Franchis R, Colombo M, Mannucci PM. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. *Gastroenterology* 2009; **137**: 2105-2111 [PMID: 19706293 DOI: 10.1053/j.gastro.2009.08.045]

40 **Tripodi A**, Primignani M, Lemma L, Chantarangkul V, Mannucci PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. *J Hepatol* 2013; **59**: 265-270 [PMID: 23583273 DOI: 10.1016/j.jhep.2013.03.036]

41 **Tripodi A**, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. *J Thromb Haemost* 2011; **9**: 1713-1723 [PMID: 21729237 DOI: 10.1111/j.1538-7836.2011.04429.x]

42 **Janssen HL**, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, van Hattum J, Chamuleau RA, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. *Blood* 2000; **96**: 2364-2368 [PMID: 11001884]

43 **Pasta L**, Marrone C, D'amico M, Virdone R, D'amico G, Sammarco P, Fabiano C, Pagliaro L. MTHFR C677T mutations in liver cirrhosis with and without portal vein thrombosis. *Liver Int* 2006; **26**: 269-270 [PMID: 16448467 DOI: 10.1111/j.1478-3231.2005.01215.x]

44 **Amitrano L**, Guardascione MA, Ames PR, Margaglione M, Iannaccone L, Brancaccio V, Balzano A. Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. *Thromb Haemost* 2006; **95**: 221-223 [PMID: 16493481]

45 **Romero Gómez M**, Suárez García E, López Lacomba D, Marchante I, Grande L, Castro Fernandez M. Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis. *J Clin Gastroenterol* 2000; **31**: 237-240 [PMID: 11034005 DOI: 10.1097/00004836-200010000-00011]

46 **Trum JW,** Dominique V, Gil C, Degott C, Rueff B, Santoni P, Ducroix JP, Capron JP, Bousquet O, Opolon P, Jean-Pierre B. Bacteroides bacteraemia of undertermined origin: strong association with portal vein thrombosis and cryptogenic pylephlebitis. *Eur J Gastroenterol Hepatol* 1993; **5**: 655-659 [DOI: 10.1097/00042737-199308000-00018]

47 **Lin RS**, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, Hsu WC, Huang CC, Wang SS, Lo KJ. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. *J Hepatol* 1995; **22**: 165-172 [PMID: 7790704 DOI: 10.1016/0168-8278(95)80424-2]

48 **Cirera I**, Bauer TM, Navasa M, Vila J, Grande L, Taurá P, Fuster J, García-Valdecasas JC, Lacy A, Suárez MJ, Rimola A, Rodés J. Bacterial translocation of enteric organisms in patients with cirrhosis. *J Hepatol* 2001; **34**: 32-37 [PMID: 11211904 DOI: 10.1016/S0168-8278(00)00013-1]

49 **Lamps LW**, Hunt CM, Green A, Gray GF, Washington K. Alterations in colonic mucosal vessels in patients with cirrhosis and noncirrhotic portal hypertension. *Hum Pathol* 1998; **29**: 527-535 [PMID: 9596279 DOI: 10.1016/S0046-8177(98)90071-5]

50 **Berg RD**. Bacterial translocation from the gastrointestinal tract. *Trends Microbiol* 1995; **3**: 149-154 [PMID: 7613757 DOI: 10.1016/S0966-842X(00)88906-4]

51 **Mehta G**, Gustot T, Mookerjee RP, Garcia-Pagan JC, Fallon MB, Shah VH, Moreau R, Jalan R. Inflammation and portal hypertension - the undiscovered country. *J Hepatol* 2014; **61**: 155-163 [PMID: 24657399 DOI: 10.1016/j.jhep.2014.03.014]

52 **Bellot P**, García-Pagán JC, Francés R, Abraldes JG, Navasa M, Pérez-Mateo M, Such J, Bosch J. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. *Hepatology* 2010; **52**: 2044-2052 [PMID: 20979050 DOI: 10.1002/hep.23918]

53 **Steib CJ**, Hartmann AC, v Hesler C, Benesic A, Hennenberg M, Bilzer M, Gerbes AL. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. *Lab Invest* 2010; **90**: 1024-1032 [PMID: 20212458 DOI: 10.1038/labinvest.2010.60]

54 **Violi F**, Ferro D, Basili S, Lionetti R, Rossi E, Merli M, Riggio O, Bezzi M, Capocaccia L. Ongoing prothrombotic state in the portal circulation of cirrhotic patients. *Thromb Haemost* 1997; **77**: 44-47 [PMID: 9031447]

55 **Villa E**, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, Turola E, Fornaciari G, Schianchi S, Ferrari A, Valla D. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. *Gastroenterology* 2012; **143**: 1253-60.e1-4 [PMID: 22819864 DOI: 10.1053/j.gastro.2012.07.018]

56 **Turnes J**, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell'Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. *Am J Gastroenterol* 2006; **101**: 506-512 [PMID: 16542287 DOI: 10.1111/j.1572-0241.2006.00453.x]

57 **Senzolo M**, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D, Burroughs AK. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. *Liver Int* 2009; **29**: 1189-1193 [PMID: 19508620 DOI: 10.1111/j.1478-3231.2009.02038.x]

58 **Okuda K**, Ohnishi K, Kimura K, Matsutani S, Sumida M, Goto N, Musha H, Takashi M, Suzuki N, Shinagawa T. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. *Gastroenterology* 1985; **89**: 279-286 [PMID: 4007419]

59 **Subramanyam BR**, Balthazar EJ, Lefleur RS, Horii SC, Hulnick DH. Portal venous thrombosis: correlative analysis of sonography, CT and angiography. *Am J Gastroenterol* 1984; **79**: 773-776 [PMID: 6385690]

60 **Van Gansbeke D**, Avni EF, Delcour C, Engelholm L, Struyven J. Sonographic features of portal vein thrombosis. *AJR Am J Roentgenol* 1985; **144**: 749-752 [PMID: 3883708 DOI: 10.2214/ajr.144.4.749]

61 **Sringeri R.** Incidental Portal Vein Thrombosis: Does It Impact the Surgical Outcomes Following Liver Transplantation? *Liver Transpl* 2013; **19**: S289

62 **Lee HK**, Park SJ, Yi BH, Yeon EK, Kim JH, Hong HS. Portal vein thrombosis: CT features. *Abdom Imaging* 2008; **33**: 72-79 [PMID: 17694406 DOI: 10.1007/s00261-007-9200-x]

63 **Tublin ME**, Dodd GD, Baron RL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. *AJR Am J Roentgenol* 1997; **168**: 719-723 [PMID: 9057522 DOI: 10.2214/ajr.168.3.9057522]

64 **Wallner B**, Edelman RR, Finn JP, Mattle HP. Bright pleural effusion and ascites on gradient-echo MR images: a potential source of confusion in vascular MR studies. *AJR Am J Roentgenol* 1990; **155**: 1237-1240 [PMID: 2122672 DOI: 10.2214/ajr.155.6.2122672]

65 **Englesbe MJ**, Schaubel DE, Cai S, Guidinger MK, Merion RM. Portal vein thrombosis and liver transplant survival benefit. *Liver Transpl* 2010; **16**: 999-1005 [PMID: 20677291 DOI: 10.1002/lt.22105]

66 **Berry K**, Taylor J, Liou IW, Ioannou GN. Portal vein thrombosis is not associated with increased mortality among patients with cirrhosis. *Clin Gastroenterol Hepatol* 2015; **13**: 585-593 [PMID: 25459555 DOI: 10.1016/j.cgh.2014.10.010]

67 **Dell'Era A**, Iannuzzi F, Fabris FM, Fontana P, Reati R, Grillo P, Aghemo A, de Franchis R, Primignani M. Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. *Dig Liver Dis* 2014; **46**: 152-156 [PMID: 24084343 DOI: 10.1016/j.dld.2013.08.138]

68 **Vianna RM**, Mangus RS, Kubal C, Fridell JA, Beduschi T, Tector AJ. Multivisceral transplantation for diffuse portomesenteric thrombosis. *Ann Surg* 2012; **255**: 1144-1150 [PMID: 22549750 DOI: 10.1097/SLA.0b013e31825429c0]

69 **Rodríguez-Castro KI**, Porte RJ, Nadal E, Germani G, Burra P, Senzolo M. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. *Transplantation* 2012; **94**: 1145-1153 [PMID: 23128996 DOI: 10.1097/TP.0b013e31826e8e53]

70 **Englesbe MJ,** Kubus J, Muhammad W, Sonnenday CJ, Welling T, Punch JD, Lynch RJ, Marrero JA, Pelletier SJ. Portal vein thrombosis and survival in patients with cirrhosis. *Liver Transpl* 2010; **16**: 83-90 [PMID: 20035521 DOI: 10.1002/lt.21941]

71 **Paskonis M**, Jurgaitis J, Mehrabi A, Kashfi A, Fonouni H, Strupas K, Büchler MW, Kraus TW. Surgical strategies for liver transplantation in the case of portal vein thrombosis--current role of cavoportal hemitransposition and renoportal anastomosis. *Clin Transplant* 2006; **20**: 551-562 [PMID: 16968480 DOI: 10.1111/j.1399-0012.2006.00560.x]

72 **Selvaggi G**, Weppler D, Nishida S, Moon J, Levi D, Kato T, Tzakis AG. Ten-year experience in porto-caval hemitransposition for liver transplantation in the presence of portal vein thrombosis. *Am J Transplant* 2007; **7**: 454-460 [PMID: 17229075 DOI: 10.1111/j.1600-6143.2006.01649.x]

73 **Hibi T**, Nishida S, Levi DM, Selvaggi G, Tekin A, Fan J, Ruiz P, Tzakis AG. When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases. *Ann Surg* 2014; **259**: 760-766 [PMID: 24299686 DOI: 10.1097/SLA.0000000000000252]

74 **Manzanet G**, Sanjuán F, Orbis P, López R, Moya A, Juan M, Vila J, Asensi J, Sendra P, Ruíz J, Prieto M, Mir J. Liver transplantation in patients with portal vein thrombosis. *Liver Transpl* 2001; **7**: 125-131 [PMID: 11172396 DOI: 10.1053/jlts.2001.21295]

75 **Bertelli R**, Nardo B, Montalti R, Beltempo P, Puviani L, Cavallari A. Liver transplantation in recipients with portal vein thrombosis: experience of a single transplant center. *Transplant Proc* 2005; **37**: 1119-1121 [PMID: 15848641 DOI: 10.1016/j.transproceed.2005.01.031]

76 **Doria C**, Marino IR. Acute portal vein thrombosis secondary to donor/recipient portal vein diameter mismatch after orthotopic liver transplantation: a case report. *Int Surg* 2003; **88**: 184-187 [PMID: 14717522]

77 **Doenecke A**, Tsui TY, Zuelke C, Scherer MN, Schnitzbauer AA, Schlitt HJ, Obed A. Pre-existent portal vein thrombosis in liver transplantation: influence of pre-operative disease severity. *Clin Transplant* 2010; **24**: 48-55 [PMID: 19236435 DOI: 10.1111/j.1399-0012.2009.00977.x]

78 **Robles R**, Fernandez JA, Hernández Q, Marín C, Ramírez P, Sánchez-Bueno F, Luján JA, Rodríguez JM, Acosta F, Parrilla P. Eversion thromboendovenectomy in organized portal vein thrombosis during liver transplantation. *Clin Transplant* 2004; **18**: 79-84 [PMID: 15108774 DOI: 10.1111/j.1399-0012.2004.00120.x]

79 **Florman S**, Miller CM. Live donor liver transplantation. *Liver Transpl* 2006; **12**: 499-510 [PMID: 16555328 DOI: 10.1002/lt.20754]

80 **Egawa H**, Tanaka K, Kasahara M, Takada Y, Oike F, Ogawa K, Sakamoto S, Kozaki K, Taira K, Ito T. Single center experience of 39 patients with preoperative portal vein thrombosis among 404 adult living donor liver transplantations. *Liver Transpl* 2006; **12**: 1512-1518 [PMID: 17004256 DOI: 10.1002/lt.20777]

81 **Sugawara Y**, Makuuchi M, Tamura S, Matsui Y, Kaneko J, Hasegawa K, Imamura H, Kokudo N, Motomura N, Takamoto S. Portal vein reconstruction in adult living donor liver transplantation using cryopreserved vein grafts. *Liver Transpl* 2006; **12**: 1233-1236 [PMID: 16724339 DOI: 10.1002/lt.20786]

82 **North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices.** Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. *N Engl J Med* 1988; **319**: 983-989 [PMID: 3262200 DOI: 10.1056/NEJM198810133191505]

83 **Amitrano L**, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, Romano L, Balzano A. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. *J Clin Gastroenterol* 2010; **44**: 448-451 [PMID: 19730112]

84 **Delgado MG**, Seijo S, Yepes I, Achécar L, Catalina MV, García-Criado A, Abraldes JG, de la Peña J, Bañares R, Albillos A, Bosch J, García-Pagán JC. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. *Clin Gastroenterol Hepatol* 2012; **10**: 776-783 [PMID: 22289875 DOI: 10.1016/j.cgh.2012.01.012]

85 **Senzolo M**, M Sartori T, Rossetto V, Burra P, Cillo U, Boccagni P, Gasparini D, Miotto D, Simioni P, Tsochatzis E, A Burroughs K. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. *Liver Int* 2012; **32**: 919-927 [PMID: 22435854 DOI: 10.1111/j.1478-3231.2012.02785.x]

86 **Werner KT**, Sando S, Carey EJ, Vargas HE, Byrne TJ, Douglas DD, Harrison ME, Rakela J, Aqel BA. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. *Dig Dis Sci* 2013; **58**: 1776-1780 [PMID: 23314858 DOI: 10.1007/s10620-012-2548-y]

87 **Intagliata NM**, Maitland H, Northup PG, Caldwell SH. Treating thrombosis in cirrhosis patients with new oral agents: ready or not? *Hepatology* 2015; **61**: 738-739 [PMID: 24829112 DOI: 10.1002/hep.27225]

88 **Martinez M**, Tandra A, Vuppalanchi R. Treatment of acute portal vein thrombosis by nontraditional anticoagulation. *Hepatology* 2014; **60**: 425-426 [PMID: 24395623 DOI: 10.1002/hep.26998]

89 **Garcia-Tsao G**, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Hepatology* 2007; **46**: 922-938 [PMID: 17879356 DOI: 10.1002/hep.21907]

90 **Heidbuchel H**, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. *Europace* 2013; **15**: 625-651 [PMID: 23625942 DOI: 10.1093/europace/eut083]

91 **Schulman S**, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. *N Engl J Med* 2013; **368**: 709-718 [PMID: 23425163 DOI: 10.1056/NEJMoa1113697]

92 **Agnelli G**, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013; **369**: 799-808 [PMID: 23808982 DOI: 10.1056/NEJMoa1302507]

93 **Eriksson BI**, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med* 2008; **358**: 2765-2775 [PMID: 18579811 DOI: 10.1056/NEJMoa0800374]

94 **Makris M**, Van Veen JJ, Tait CR, Mumford AD, Laffan M. Guideline on the management of bleeding in patients on antithrombotic agents. *Br J Haematol* 2013; **160**: 35-46 [PMID: 23116425 DOI: 10.1111/bjh.12107]

95 **Scaglione F**. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. *Clin Pharmacokinet* 2013; **52**: 69-82 [PMID: 23292752 DOI: 10.1007/s40262-012-0030-9]

96 **Pawlotsky JM,** Aghemo A, Dusheiko G, Forns X, Puoti M, Sarrazin C. EASL recommendations on treatment of hepatitis C-2014. In 49th Annual Meeting of the European Association for the Study of the Liver, London, United Kingdom. April 2014 (pp. 9-13)

97 **Potze W,** Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. *Hepatology* 2015; **61**: 1435-1436 [DOI: 10.1002/hep.27350]

98 **Martinez M,** Tandra A, Vuppalanchi R. Re: HEP-14-1844.R1 - treatment of portal vein thrombosis by non-traditional anticoagulation. *Hepatology* 2014; Epub ahead of print [PMID: 25266638 DOI: 10.1002/hep.27351]

99 **Han G**, Qi X, He C, Yin Z, Wang J, Xia J, Yang Z, Bai M, Meng X, Niu J, Wu K, Fan D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. *J Hepatol* 2011; **54**: 78-88 [PMID: 20932597 DOI: 10.1016/j.jhep.2010.06.029]

100 **Perarnau JM**, Baju A, D'alteroche L, Viguier J, Ayoub J. Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis. *Eur J Gastroenterol Hepatol* 2010; **22**: 1093-1098 [PMID: 20308910 DOI: 10.1097/MEG.0b013e328338d995]

101 **D'Avola D**, Bilbao JI, Zozaya G, Pardo F, Rotellar F, Iñarrairaegui M, Quiroga J, Sangro B, Herrero JI. Efficacy of transjugular intrahepatic portosystemic shunt to prevent total portal vein thrombosis in cirrhotic patients awaiting for liver transplantation. *Transplant Proc* 2012; **44**: 2603-2605 [PMID: 23146469 DOI: 10.1016/j.transproceed.2012.09.050]

102 **Luca A,** Miraglia R, Caruso S, Milazzo M, Sapere C, Maruzzelli L, Vizzini G, Tuzzolino F, Gridelli B, Bosch J.Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. *Gut* 2011; **60**: 846-52 [PMID: 21357252 DOI: 10.1136/gut.2010.228023]

103 **Bauer J**, Johnson S, Durham J, Ludkowski M, Trotter J, Bak T, Wachs M. The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis. *Liver Transpl* 2006; **12**: 1544-1551 [PMID: 17004250 DOI: 10.1002/lt.20869]

104 **Senzolo M**, Tibbals J, Cholongitas E, Triantos CK, Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. *Aliment Pharmacol Ther* 2006; **23**: 767-775 [PMID: 16556179 DOI: 10.1111/j.1365-2036.2006.02820.x]

105 **Wang Z,** Zhao H, Wang X, Zhang H, Jiang M, Tsauo J, Luo X, Yang L, Li X.Clinical outcome comparison between TIPS and EBL in patients with cirrhosis and portal vein thrombosis. *Abdom Imaging* 2014; Epub ahead of print [PMID: 25504374 DOI: 10.1007/s00261-014-0320-9]

106 **Van Ha TG**, Hodge J, Funaki B, Lorenz J, Rosenblum J, Straus C, Leef J. Transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis and concomitant portal vein thrombosis. *Cardiovasc Intervent Radiol* 2006; **29**: 785-790 [PMID: 16850140 DOI: 10.1007/s00270-005-0090-4]

107 **Ferral H**, Gamboa P, Postoak DW, Albernaz VS, Young CR, Speeg KV, McMahan CA. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. *Radiology* 2004; **231**: 231-236 [PMID: 14990811 DOI: 10.1148/radiol.2311030967]

108 **Clavien PA**, Selzner M, Tuttle-Newhall JE, Harland RC, Suhocki P. Liver transplantation complicated by misplaced TIPS in the portal vein. *Ann Surg* 1998; **227**: 440-445 [PMID: 9527068 DOI: 10.1097/00000658-199803000-00017]

109 **Boyer TD**, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. *Hepatology* 2005; **41**: 386-400 [PMID: 15660434 DOI: 10.1002/hep.20559]

110 **DeLeve LD**, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. *Hepatology* 2009; **49**: 1729-1764 [PMID: 19399912 DOI: 10.1002/hep.22772]

111 **Hollingshead M**, Burke CT, Mauro MA, Weeks SM, Dixon RG, Jaques PF. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. *J Vasc Interv Radiol* 2005; **16**: 651-661 [PMID: 15872320 DOI: 10.1097/01.RVI.0000156265.79960.86]

112 **Malkowski P**, Pawlak J, Michalowicz B, Szczerban J, Wroblewski T, Leowska E, Krawczyk M. Thrombolytic treatment of portal thrombosis. *Hepatogastroenterology* 2003; **50**: 2098-2100 [PMID: 14696472]

113 **De Santis A**, Moscatelli R, Catalano C, Iannetti A, Gigliotti F, Cristofari F, Trapani S, Attili AF. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: a pilot study. *Dig Liver Dis* 2010; **42**: 451-455 [PMID: 19819770 DOI: 10.1016/j.dld.2009.08.009]

114 **Blum U**, Haag K, Rössle M, Ochs A, Gabelmann A, Boos S, Langer M. Noncavernomatous portal vein thrombosis in hepatic cirrhosis: treatment with transjugular intrahepatic portosystemic shunt and local thrombolysis. *Radiology* 1995; **195**: 153-157 [PMID: 7892458 DOI: 10.1148/radiology.195.1.7892458]

115 **Krag A**, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease. *Gut* 2012; **61**: 967-969 [PMID: 22234982 DOI: 10.1136/gutjnl-2011-301348]

116 **Rasaratnam B**, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. *Ann Intern Med* 2003; **139**: 186-193 [PMID: 12899586 DOI: 10.7326/0003-4819-139-3-200308050-00008]

117 **Vairappan B,** Sharama V, Winstanley A, Davies N, Shah N, Jalan R. Modulation of the DDAH-ADMA pathway with the Farnesoid X receptor (FXR) agonist INT-747 restores hepatic eNOS activity and lowers portal pressure in cirrhotic rats. *Hepatology* 2009; **50**: 336A–337A



118 **European Association for The Study Of The Liver;** European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; **56**: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]

119 **Kinjo N**, Kawanaka H, Akahoshi T, Matsumoto Y, Kamori M, Nagao Y, Hashimoto N, Uehara H, Tomikawa M, Shirabe K, Maehara Y. Portal vein thrombosis in liver cirrhosis. *World J Hepatol* 2014; **6**: 64-71 [PMID: 24575165]



**P-Reviewer:** Ishibashi H, McNally RJQ, Toshikuni N **S-Editor:** Qi Y

**L-Editor: E-Editor:**

**Figure 1 Yerdel’s Classfication of portal vein thrombosis[15].** A: Grade I portal vein thrombosis. Partial portal vein thrombosis (< 50% lumen) with or without minimal extension in to the superior mesenteric vein (SMV); B: Grade II portal vein thrombosis; > 50% occlusion with or without minimal extension into the SMV;C: Complete thrombosis of both portal vein and proximal SMV. Distal SMV is open; D: Complete thrombosis of portal vein, proximal and distal SMV.

A B

C D

**Table 1 Key studies of portal vein thrombosis and liver transplantation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Number of patients** | **Prevalence PVT, *n* (%)** | **PVT characteristics** | **Outcomes** |
| Englesbe  *et al*[65] | 22291  (2001-2007) | 897 (4.02) | Not described | PVT was not predictive of waiting list mortality (HR = 0.90, *P* = 0.23). PVT was predictive of post-transplant mortality **(**HR = 1.32, *P* = 0.02) |
| Sringeri  *et al*[61] | 1491  (2000-Aug 2012) | 119 (8) | Not described | Prolonged theatre timea, increased blood transfusion ratesa. No difference mortality up-to 140 mo |
| Ravaioli  *et al*[13] | 889  (1998-2008) | 91 (10.2) | Partial 51 (56%)  Complete 40 (44%) | No difference 1 yr (85% *vs* 86%) and 5 year (68% *vs* 73%) survival between PVT and non-PVT subjects.  Survival improved significantly for patients with complete PVT in the second era (2003-08) (57% *vs* 89% at 1 yra). |
| Yerdel  *et al*[15] | 779  (1987-1996) | 63 (8.1) | Grade 1: 24,  Grade 2: 23,  Grade 3: 6,  Grade 4: 10 | Reduced 5 year survival between PVT and non-PVT subjects (65.3% *vs* 76.3%a).  But improved 5 yr survival from 1st to 2nd era in all patients (from 72% to 83%a). |

a*P* < 0.05. PVT: Portal vein thrombosis.

**Table 2 Summary of new oral anti-coagulants**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name** | **Dabigatran** | **Apixaban** | **Edoxaban** | **Rivaroxaban** |
| Action | Direct thrombin inhibitor | Activated Factor Xa inhibitor | Activated Factor Xa inhibitor | Activated Factor Xa inhibitor |
| Clearance | 80% renal clearance | 73% hepatic  27% renal clearance | 50% hepatic  50% renal clearance | 65% hepatic  35% renal clearance |
| CYP3A4 interaction? | No | Yes (minor) | Minimal | Yes |
| Absorption with food? | No effect | No effect | Up to 20% more | 40% more therefore intake with food |
| Elimination half life | 12-17 h | 12 hr | 9-11 h | 8-9 h young  11-13 h elderly |

**Table 3 Summary of studies reporting the use of anticoagulation for portal vein thrombosis in cirrhosis**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Study type** | **Number**  **(controls)** | **Baseline severity liver disease** | **Duration and type anticoagulation** | **PVT characteristics**  **(none/partial/complete occlusion)** | **Recannalisation** | **Partial recannalisation/ stabilisation** | **Progression** | **Bleeding complicaitons** |
| Francoz  *et al*[7] | Prospective case control | 19 (10) | mean MELD 12.8 | Warfarin (INR 2-3)  Mean 8.1 months | 0/ 18/ 1 | 8/19 (42%) *vs* 0/10 non-anti-coagulated (*P* = 0.002) | 0 | 1 | 1 bleeding episode following endoscopic variceal band ligation |
| Amitrano  *et al*[83] | Prospective | 28 | **?** | Enoxaparin 200IU/kg per day: 6 months for responders and non-responders. Partial responders continue until end of follow up. | 0/ 23/ 5 | 21 (75%) at median 11 months | 5 (17.9%) | 2 | Mild anaemia in patient with portal hypertensive gastropathy |
| Delgado  *et al*[84] | Retrospective | 55 | mean MELD 12.8 +/-3.8 | Warfarin (INR 2-3) or enoxaparin  mean 6.8 mo | 0/ 41/ 14 | 25 (45.5%) | 30 (54.5%) | 0 | 6 variceal bleeds\*, 1 lower GI bleed, 1 obscure GI bleed, 1 oral bleed post-dental extraction, 1 severe vaginal bleed |
| Senzolo  *et al*[85] | Prospective case control | 33 (21) | MELD 12.6 (controls MELD 13.7) | Nadraparin low molecular weight heparin until end of follow up, or until 6 months following complete recannalisation. | 0/ 24/ 11 | 12/33 (36%) active arm *vs* 1/21 (5%) controls | Partial: 9/33 active arm. Stabilisation: 7/33 active arm. Partial recannalisation or stabilisation in 5/21 controls. | 5/33 (14.3%) active arm *vs* 15/21 (71.4%) control arm (*P* < 0.001) | Active arm: 1 cerebral haemorrhage, 1 epistaxis, 1 haematuria, 1 variceal bleed  Control arm: 5 variceal bleeds |
| Werner  *et al*[86] | Retrospective | 28 | MELD 7-29 | Warfarin  Mean 302 days | not described | 11 (39.3%) | 17 (60.7%) | 0 | 1 significant vaginal bleed |
| Villa  *et al*[55] | Prospective randomised controlled trial | 34 (36) | Child’s 7-10 | Enoxaparin 4000 IU/d  48 wk treatment. Follow up to 2 yrs | Primary prevention study: No PVTs at baseline | N/A | N/A | Treatment arm: No PVT at 2 yr. Control arm: PVT in 10/36 (27.8%) at 2 years (*P* = 0.001) | Active arm: 2 variceal bleeds, 2 epistaxis  Control arm: 1 variceal bleed, 1 epistaxis |

PVT: Portal vein thrombosis.

**Table 4 Summary of retrospective case series reporting the use of transjugular intrahepatic portosystemic stent-shunt for portal vein thrombosis in cirrhosis**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Study type and stent characteristics** | **Number** | **Baseline severity liver disease: Child’s A/B/C (%)** | **TIPSS indication (%)** | **PVT characteristics: complete/ partial/ cavernoma (%)** | **Successful cannulation (%)** | **Outcome** | **Significant complications/ notes** |
| Luca *et al*[102] | Series 2003-2010  13 bare Wallstent, 57 covered Viatorr ePTFE covered (*WL Gore and Associates*) | 70 | A:17 (24)  B:42 (60)  C:11 (16) | Bleeding: 48  Ascites/ hydrothorax: 18  Specific treatment of PVT: 4 | Complete: 24  Cavernoma: 2 | 70/70 (100) cannulation.  Complete recannalisation or significant reduction in thrombosis: 61 (87) | Complete recannalisation in 40 (57%): 38 maintained patency at mean follow up 20.7 months. |  |
| Perarnau  *et al*[100] | Series 1990-2004  Palmaz (*Cordis*) or Wallstent (*Boston Scientific*) bare stents | 34 | A:3 (14)  B:11 (52)  C:7 (33)  (incomplete details) | Bleeding: 27 (79)  Ascites: 5 (15)  Other: 2 | Complete acute: 15  Complete + cavernoma: 19 | No cavernoma: 15/15 (100)  Cavernoma: 12/19 (63) | Mean F/U 30 months.  26/34 (72%) long-term patency | Failed cannulation in presence of thrombosed intrahepatic PV branches or peri-hilar cavernoma |
| Senzolo  *et al*[104] | Series 1994-2005  26 Memotherms (*Angiomed*) bare stents, 3 Viatorr covered stents | 28 (15 non-cirrhotic) | Not stated | Bleeding: 15  Ascites: 5  Portal biliopathy: 3  Specific treatment PVT: 1 | Complete: 8 ( ) [3 with, 5 without cavernoma]  Partial: 5 | 19/28 (73%) | Primary patency mean 18 months in 14/19.  Stent thrombosis in 2 non-cirrhotic subjects (Budd-Chiari syndrome) |  |
| Han  *et al*[99] | Series 2001-2008  Uncovered stents in all patients | 57 | A:25 (44)  B:26 (46)  C:6 (30) | Bleeding: 56  Ascites: 1 | Complete: 14  Cavernoma: 30  Partial: 35 | Overall: 43/57 (75)  Complete PVT: 8/14 (57)  Partial PVT: 35/35 (100)  Cavernoma: 16/30 (53%) | Primary patency maintained in 26/43 (17 required shunt revisions to maintain patency) | Failure related to presence of cavernoma.  1 case of delayed severe intra-abdominal haemorrhage following percutaneous trans-hepatic approach. |
| Van Ha  *et al*[106] | Series 1995-2003  12 bare Wallstent (*Boston Scientific*), 1 bare Zilver stent (*Cook*) | 15 | B:11 (73)  C:4 (27) | Bleeding: 10  Ascites: 5 | Complete: 4/ partial: 7/ complete with cavernoma: 4 | Overall: 13/15 (87)  Cavernoma: 3/4  No cavernoma: 10/11 (91) | Mean F/U 17months.  1 stent occlusion |  |
| D’Avola  *et al*[101] | Series 1995-2009  Bare and covered stents | 15 (+ 8 controls with PVT) | Mean Child’s 8 | Prevention of complete PVT pre-liver transplant: 8  Bleeding: 6  Ascites: 1 | All partial PVT | Series describes only patients who successfully underwent TIPS | 3/15 TIPSS thrombosis: all successfully treated.  Median time TIPSS to transplant: 185 days.  100% portal vein patency at time of transplant *vs* 50% patency at transplant in controls (*P* = 0.008) |  |
| Bauer  *et al*[103] | Series 1999-2005  3 covered stents: others bare stent | 9 | Cirrhosis: disease severity not stated | Primary indication: maintain PV patency for future liver transplantation | Complete: 7  Partial: 2  Cavernoma: 4 | Series describing only patients who successfully underwent TIPS | 1/9 re-thrombosed.  2 patients transplanted with no PVT present |  |
| Blum  *et al*[114] | Case series  All bare stents | 7 | Cirrhosis: disease severity not stated | Bleeding: 7 | PVT severity not stated.  No cavernoma. | Series of successful cases |  |  |

PVT: Portal vein thrombosis; TIPSS: transjugular intrahepatic portosystemic stent-shunt.

.